Please sign in to follow a disease.
Rollover trial tests continued sitravatinib combo for advanced cancers
NCT ID NCT04887870
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at the safety and effectiveness of continuing sitravatinib, a targeted cancer drug, either alone or combined with other therapies like nivolumab or pembrolizumab, in people with advanced or metastatic solid tumors. It enrolled 52 patients who were already benefiting from sitravatinib in a previous study. The main goal was to track side effects and how long the cancer stayed under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sitravatinib (a targeted therapy) alone or combined with other anticancer drugs like nivolumab or pembrolizumab
What this could lead to
If successful, this could show that continuing sitravatinib-based treatment is safe and may help control advanced cancers for longer.
What could go wrong
This is a small rollover study (52 people) that only included patients already benefiting from treatment. Results may not apply to all patients, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Local Institution - 516-014-001
Austin, Texas, 78758, United States
-
Local Institution - 516-014-002
Boston, Massachusetts, 02215, United States
-
Local Institution - 516-014-004
Columbus, Ohio, 43210, United States
-
Local Institution - 516-014-005
Minneapolis, Minnesota, 55455, United States
-
Local Institution - 516-014-011
Albany, New York, 12208, United States
-
Local Institution - 516-014-013
Houston, Texas, 77030, United States
-
Local Institution - 516-014-029
Goshen, Indiana, 46526, United States
-
Memorial Sloan Kettering Cancer Center - Arnold and Marie Schwartz Cancer Research Building
New York, New York, 10065, United States
-
NEXT Virginia
Fairfax, Virginia, 22031, United States
-
Rocky Mountain Cancer Centers - Littleton
Littleton, Colorado, 80218, United States
-
USOR - Texas Oncology Northeast Texas - Denison
Denison, Texas, 75020, United States
-
Urology Cancer Center and GU Research Network
Omaha, Nebraska, 68130, United States